Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

858 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma.
Honda Y, Otsuka A, Ono S, Yamamoto Y, Seidel JA, Morita S, Hirata M, Kataoka TR, Takenouchi T, Fujii K, Kanekura T, Okubo Y, Takahashi K, Yanagi T, Hoshina D, Hata H, Abe R, Fujimura T, Funakoshi T, Yoshino K, Masuzawa M, Amoh Y, Tanaka R, Fujisawa Y, Honda T, Kabashima K. Honda Y, et al. Among authors: fujisawa y. Oncoimmunology. 2016 Nov 4;6(1):e1253657. doi: 10.1080/2162402X.2016.1253657. eCollection 2017. Oncoimmunology. 2016. PMID: 28197370 Free PMC article.
Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab.
Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Fujimura T, Yamamoto Y, Hata H, Gosho M, Tanaka R, Yamaguchi K, Nonomura Y, Hirai I, Furudate S, Okuhira H, Imafuku K, Aoki M, Matsushita S. Fujisawa Y, et al. J Dermatol Sci. 2017 Nov;88(2):225-231. doi: 10.1016/j.jdermsci.2017.07.007. Epub 2017 Jul 16. J Dermatol Sci. 2017. PMID: 28736218
Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Uchi H, Fujimura T, Matsushita S, Hata H, Okuhira H, Tanaka R, Nagai K, Ishida Y, Nakamura Y, Furudate S, Yamamura K, Imafuku K, Yamamoto Y. Fujisawa Y, et al. J Dermatol Sci. 2018 Jan;89(1):60-66. doi: 10.1016/j.jdermsci.2017.10.009. Epub 2017 Oct 25. J Dermatol Sci. 2018. PMID: 29079332
Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.
Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Fujimura T, Yamamoto Y, Hata H, Tanaka R, Yamaguchi K, Nonomura Y, Hirai I, Furudate S, Okuhira H, Imafuku K, Aoki M, Matsushita S. Fujisawa Y, et al. Br J Dermatol. 2018 Jul;179(1):213-215. doi: 10.1111/bjd.16427. Epub 2018 Apr 24. Br J Dermatol. 2018. PMID: 29405254 No abstract available.
Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer.
Fujimura T, Kambayashi Y, Fujisawa Y, Hidaka T, Aiba S. Fujimura T, et al. Among authors: fujisawa y. Front Oncol. 2018 Jan 23;8:3. doi: 10.3389/fonc.2018.00003. eCollection 2018. Front Oncol. 2018. PMID: 29410946 Free PMC article. Review.
Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study.
Fujimura T, Sato Y, Tanita K, Kambayashi Y, Otsuka A, Fujisawa Y, Yoshino K, Matsushita S, Funakoshi T, Hata H, Yamamoto Y, Uchi H, Nonomura Y, Tanaka R, Aoki M, Imafuku K, Okuhira H, Furudate S, Hidaka T, Aiba S. Fujimura T, et al. Among authors: fujisawa y. Oncotarget. 2018 Feb 15;9(21):15542-15551. doi: 10.18632/oncotarget.24509. eCollection 2018 Mar 20. Oncotarget. 2018. PMID: 29643991 Free PMC article.
858 results